Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after one prior chemotherapy regimen: Results of Lume-Lung 1, a randomized, double-blind, phase III trial.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA8011-LBA8011
Author(s):  
Martin Reck ◽  
Rolf Kaiser ◽  
Anders Mellemgaard ◽  
Jean Yves Douillard ◽  
Sergey Orlov ◽  
...  
Keyword(s):  
Chemotherapy Regimen ◽  
Phase Iii ◽  
Double Blind ◽  
Daily News ◽  
Phase Iii Trial ◽  
Prior Chemotherapy ◽  
Prior Chemotherapy Regimen ◽  
Nsclc Patients ◽  
Final Text ◽  
Bibf 1120

LBA8011 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Interim analysis of The Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small-cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC)

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA8002-LBA8002
Author(s):  
Teresa Moran ◽  
Manuel Cobo ◽  
Manuel Domine ◽  
Maria Sanchez-Ronco ◽  
Isabel Bover ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Interim Analysis ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Daily News ◽  
Phase Iii Trial ◽  
Cancer Group ◽  
Nsclc Patients ◽  
Final Text

LBA8002 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA5503-LBA5503
Author(s):  
Andreas Du Bois ◽  
Anne Floquet ◽  
Jae Weon Kim ◽  
Jörn Rau ◽  
Jose Maria Del Campo ◽  
...  
Keyword(s):  
Phase Iii ◽  
First Line ◽  
Double Blind ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Peritoneal Cancer ◽  
Intergroup Trial ◽  
Final Text ◽  
Line Chemotherapy

LBA5503 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Saturday, June 1, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA7501-LBA7501
Author(s):  
Marina Chiara Garassino ◽  
Olga Martelli ◽  
Anna Bettini ◽  
Irene Floriani ◽  
Elena Copreni ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Phase Iii ◽  
Line Treatment ◽  
Second Line ◽  
Wild Type ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Nsclc Patients ◽  
Final Text

LBA7501 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. CRA1002-CRA1002 ◽  
Author(s):  
Hope S. Rugo ◽  
William Thomas Barry ◽  
Alvaro Moreno-Aspitia ◽  
Alan P. Lyss ◽  
Constance Cirrincione ◽  
...  
Keyword(s):  
Metastatic Breast ◽  
Phase Iii ◽  
First Line ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
First Line Therapy ◽  
Line Therapy ◽  
Locally Recurrent ◽  
Final Text

CRA1002 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA5002-LBA5002 ◽  
Author(s):  
Eric Pujade-Lauraine ◽  
Felix Hilpert ◽  
Béatrice Weber ◽  
Alexander Reuss ◽  
Andres Poveda ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Recurrent Ovarian Cancer ◽  
Phase Iii ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Final Text

LBA5002^ The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients with metastatic colorectal cancer (mCRC): Efficacy and safety results of the international GERCOR DREAM phase III trial.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA3500-LBA3500
Author(s):  
Christophe Tournigand ◽  
Benoit Samson ◽  
Werner Scheithauer ◽  
Gérard Lledo ◽  
Frédéric Viret ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Maintenance Therapy ◽  
Phase Iii ◽  
Efficacy And Safety ◽  
First Line ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Final Text ◽  
Line Chemotherapy

LBA3500^ The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. LBA9007-LBA9007 ◽  
Author(s):  
Tony Mok ◽  
Ying Cheng ◽  
Xiangdong Zhou ◽  
Ki Hyeong Lee ◽  
Kazuhiko Nakagawa ◽  
...  
Keyword(s):  
Egfr Mutation ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
First Line ◽  
Open Label ◽  
Daily News ◽  
Phase Iii Trial ◽  
Open Label Phase ◽  
Final Text

The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Monday, June 5, 2017, and in the Annual Meeting Proceedings online supplement to the June 20, 2017, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA4500-LBA4500
Author(s):  
Karim Fizazi ◽  
Lance C. Pagliaro ◽  
Aude Flechon ◽  
Jozef Mardiak ◽  
Lionnel Geoffrois ◽  
...  
Keyword(s):  
Germ Cell ◽  
Poor Prognosis ◽  
Germ Cell Tumors ◽  
Phase Iii ◽  
Serum Tumor Marker ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Personalized Chemotherapy ◽  
Final Text

LBA4500 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Saturday, June 1, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Phase III trial of a 3-weekly versus 5-weekly schedule of S-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOS study.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA4024-LBA4024
Author(s):  
Min-Hee Ryu ◽  
Eishi Baba ◽  
Kyung Hee Lee ◽  
Narikazu Boku ◽  
Young Iee Park ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase Iii ◽  
Weekly Schedule ◽  
Line Treatment ◽  
First Line ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Final Text ◽  
First Line Treatment

LBA4024 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Randomized phase III trial of imatinib (IM) rechallenge versus placebo in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): Right study.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA10502-LBA10502
Author(s):  
Yoon-Koo Kang ◽  
Min-Hee Ryu ◽  
Baek-Yeol Ryoo ◽  
Hyun Jin Kim ◽  
Jong Jin Lee ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Stromal Tumor ◽  
Phase Iii ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Final Text

LBA10502 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Sign in / Sign up

Export Citation Format

Share Document